SPOTLIGHT: Sangamo targets gene manipulation

Forbes has highlighted the development work of Sangamo BioSciences, which has a "hefty" pipeline of drug candidates in development that use zinc-finger DNA binding proteins to manipulate genes for a number of diseases which currently can't be treated. Report

Suggested Articles

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.

RA Capital 's 15-month old inaugural venture fund that has already seen 25% of its portfolio companies IPO or be acquired.